Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12538844rdf:typepubmed:Citationlld:pubmed
pubmed-article:12538844lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:12538844lifeskim:mentionsumls-concept:C0018787lld:lifeskim
pubmed-article:12538844lifeskim:mentionsumls-concept:C1522642lld:lifeskim
pubmed-article:12538844lifeskim:mentionsumls-concept:C0032824lld:lifeskim
pubmed-article:12538844lifeskim:mentionsumls-concept:C0288171lld:lifeskim
pubmed-article:12538844lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:12538844lifeskim:mentionsumls-concept:C1314939lld:lifeskim
pubmed-article:12538844pubmed:issue2lld:pubmed
pubmed-article:12538844pubmed:dateCreated2003-1-22lld:pubmed
pubmed-article:12538844pubmed:abstractTextWe studied the effects of irbesartan, a selective angiotensin II type 1 receptor antagonist, on human ether-a-go-go-related gene (HERG), KvLQT1+minK, hKv1.5, and Kv4.3 channels using the patch-clamp technique. Irbesartan exhibited a low affinity for HERG and KvLQT1+minK channels (IC(50) = 193.0 +/- 49.8 and 314.6 +/- 85.4 microM, respectively). In hKv1.5 channels, irbesartan produced two types of block, depending on the concentration tested. At 0.1 microM, irbesartan inhibited the current in a time-dependent manner (22 +/- 3.9% at +60 mV). The blockade increased steeply with channel activation increasing at more positive potentials. However, at 10 microM, irbesartan induced a time-independent blockade that occurred in the range of potentials of channel opening, reaching its maximum at approximately 0 mV, and remaining unchanged at more positive potentials (24.0 +/- 1.0% at +60 mV). In Kv4.3 currents, irbesartan produced a concentration-dependent block, which resulted in two IC(50) values (1.0 +/- 0.1 nM and 7.2 +/- 0.6 microM). At 1 microM, it inhibited the peak current and accelerated the time course of inactivation, decreasing the total charge crossing the membrane (36.6 +/- 7.8% at +50 mV). Irbesartan shifted the inactivation curve of Kv4.3 channels, the blockade increasing as the amount of inactivated channels increased. Molecular modeling was used to define energy-minimized dockings of irbesartan to hKv1.5 and HERG channels. In conclusion, irbesartan blocks Kv4.3 and hKv1.5 channels at therapeutic concentrations, whereas the blockade of HERG and KvLQT1+minK channels occurred only at supratherapeutic levels. In hKv1.5, a receptor site is apparent on each alpha-subunit of the channel, whereas in HERG channels a common binding site is present at the pore.lld:pubmed
pubmed-article:12538844pubmed:languageenglld:pubmed
pubmed-article:12538844pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12538844pubmed:citationSubsetIMlld:pubmed
pubmed-article:12538844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12538844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12538844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12538844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12538844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12538844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12538844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12538844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12538844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12538844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12538844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12538844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12538844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12538844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12538844pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12538844pubmed:statusMEDLINElld:pubmed
pubmed-article:12538844pubmed:monthFeblld:pubmed
pubmed-article:12538844pubmed:issn0022-3565lld:pubmed
pubmed-article:12538844pubmed:authorpubmed-author:IriepaIsabelIlld:pubmed
pubmed-article:12538844pubmed:authorpubmed-author:GálvezEnrique...lld:pubmed
pubmed-article:12538844pubmed:authorpubmed-author:DelpónEvaElld:pubmed
pubmed-article:12538844pubmed:authorpubmed-author:AriasCristina...lld:pubmed
pubmed-article:12538844pubmed:authorpubmed-author:CaballeroRica...lld:pubmed
pubmed-article:12538844pubmed:authorpubmed-author:MorenoIgnacio...lld:pubmed
pubmed-article:12538844pubmed:authorpubmed-author:TamargoJuanJlld:pubmed
pubmed-article:12538844pubmed:authorpubmed-author:GonzálezTeres...lld:pubmed
pubmed-article:12538844pubmed:authorpubmed-author:ValenzuelaCar...lld:pubmed
pubmed-article:12538844pubmed:issnTypePrintlld:pubmed
pubmed-article:12538844pubmed:volume304lld:pubmed
pubmed-article:12538844pubmed:ownerNLMlld:pubmed
pubmed-article:12538844pubmed:authorsCompleteYlld:pubmed
pubmed-article:12538844pubmed:pagination862-73lld:pubmed
pubmed-article:12538844pubmed:dateRevised2008-10-28lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:meshHeadingpubmed-meshheading:12538844...lld:pubmed
pubmed-article:12538844pubmed:year2003lld:pubmed
pubmed-article:12538844pubmed:articleTitleEffects of irbesartan on cloned potassium channels involved in human cardiac repolarization.lld:pubmed
pubmed-article:12538844pubmed:affiliationDepartment of Pharmacology, School of Medicine, Universidad Complutense, Madrid, Spain.lld:pubmed
pubmed-article:12538844pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12538844pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12538844lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12538844lld:pubmed